Literature DB >> 3338565

Preformed PAF-acether and lyso PAF-acether are bound to blood lipoproteins.

J Benveniste1, D Nunez, P Duriez, R Korth, J Bidault, J C Fruchart.   

Abstract

PAF-acether (PAF) is a newly formed mediator not normally present in circulating blood. A compound exhibiting all of its biological characteristics but coeluting with phosphatidylcholine (PC) in high-pressure liquid chromatography (HPLC) was unveiled ('peak X') in normal human plasma. A second HPLC run of peak X HPLC fractions revealed the presence of PAF itself with concomitant disappearance of peak X. Beside PAF, immunoreactive apolipoproteins A-I and E were found in peak X. Also lipoproteins (Ls) purified using either ultracentrifugation or immunoaffinity chromatography yielded peak X and, in a second HPLC run, authentic PAF. L-free plasma was devoid of peak X. Finally, after preincubation with plasma, labeled PAF was found associated with Ls. Thus in human blood preformed PAF is bound in high amounts to Ls, a result of interest given the role of Ls and platelets in vascular diseases and the present knowledge on PAF biosynthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338565     DOI: 10.1016/0014-5793(88)81456-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

1.  Blood polymorphonuclear leukocyte activation in atherosclerosis: effects of aspirin.

Authors:  G Egger; A Burda; A Obernosterer; H Mitterhammer; G Kager; G Jürgens; H P Hofer; J S Fabjan; E Pilger
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

Review 2.  Necrotizing enterocolitis: Pathophysiology from a historical context.

Authors:  David Hackam; Michael Caplan
Journal:  Semin Pediatr Surg       Date:  2017-11-06       Impact factor: 2.754

Review 3.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

4.  Occupancy of platelet receptors for platelet-activating factor in patients with septicemia.

Authors:  F Lopez Diez; M L Nieto; S Fernandez-Gallardo; M A Gijon; M Sanchez Crespo
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

Authors:  J M Heery; M Kozak; D M Stafforini; D A Jones; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Intravascular release of a platelet-activating factor-like lipid (PAF-LL) induced by cigarette smoking.

Authors:  T Imaizumi
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

7.  Presence of paf-acether in rheumatic diseases.

Authors:  P Hilliquin; C J Menkes; S Laoussadi; J Benveniste; B Arnoux
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  A simple and precise method for the routine determination of platelet-activating factor in blood and urine.

Authors:  C A Demopoulos; N K Andrikopoulos; S Antonopoulou
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

9.  Platelet-activating factor type activity in plasma from patients with septicemia and other diseases.

Authors:  H O Heuer; H Darius; H F Lohmann; J Meyer; M Schierenberg; N Treese
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.